SCHEMBL15210347

SCHEMBL15210347

COc1cc(-c2cc3nccc(N(C)C4CCCNC4)c3o2)cc(OC)c1OC

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.35
OPRK1 P41145 1/20 0.35
SYK P43405 8/20 0.35
GAK O14976 1/20 0.35
RIPK2 O43353 1/20 0.35
STK16 O75716 1/20 0.35
EGFR P00533 1/20 0.35
AAK1 Q2M2I8 1/20 0.35
BMP2K Q9NSY1 1/20 0.35
NLK Q9UBE8 1/20 0.35
IRAK3 Q9Y616 1/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
HTR2A P28223 1/20 0.34
CYP1A1 P04798 3/20 0.33
CYP1B1 Q16678 3/20 0.33
CYP1A2 P05177 1/20 0.33
CCNT1 O60563 1/20 0.33
CDK9 P50750 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL721675 0.86 PDE4C (0.37) SYKHTR2ACCNT1CDK9TGFBR1
SCHEMBL15210345 0.77 ROCK2 (0.43) SYK
SCHEMBL10267561 0.74 MAPK1 (0.41) MAPK1OPRK1CCNT1CDK9
SCHEMBL723083 0.74 TGFBR1 (0.46) SYKCYP1A1CYP1B1CYP1A2CCNT1
SCHEMBL15210404 0.73 SYK (0.40) SYKCCNT1CDK9
SCHEMBL721674 0.73 SYK (0.40) SYKCCNT1CDK9
SCHEMBL723093 0.70 PDE4C (0.55) SYKCYP1A1CYP1B1CYP1A2CCNB2
SCHEMBL10266957 0.70 PRKCI (0.41) CYP1A2
SCHEMBL15210578 0.70 NCF1 (0.55) RIPK2EGFRNLKTGFBR1ACVR1
SCHEMBL18040411 0.70 CCNT1 (0.33) MAPK1OPRK1SYKCCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2817313-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-09-07 EP claimed
US-20150038527-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-02-05 US claimed
EP-2817313-A1 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2014-12-31 EP claimed
WO-2013124025-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-08-29 WO claimed
EP-2817313-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-09-07 EP disclosed
US-20150038527-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-02-05 US disclosed
EP-2817313-A1 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2014-12-31 EP disclosed
WO-2013124025-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038527-A1 FUROPYRIDINE DERIVATIVES SYK, LYN, BTK MAPK1 483/4885OPRK1 3931/4885SYK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.